May 15 |
Galectin Therapeutics GAAP EPS of -$0.19
|
May 15 |
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
|
May 13 |
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
|
Apr 23 |
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
|
Apr 9 |
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
|